Calliditas Therapeutics Ab Stock Net Income
| CLTEF Stock | USD 0.59 0.00 0.00% |
As of the 24th of January, Calliditas Therapeutics shows the Downside Deviation of 24.61, mean deviation of 81.18, and Risk Adjusted Performance of 0.1584. Calliditas Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Calliditas Therapeutics variance and the relationship between the treynor ratio and expected short fall to decide if Calliditas Therapeutics is priced correctly, providing market reflects its regular price of 0.59 per share. As Calliditas Therapeutics is a penny stock we also strongly suggest to validate its total risk alpha numbers.
Calliditas Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Calliditas Therapeutics' valuation are provided below:Calliditas Therapeutics AB does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Calliditas |
Search Suggestions
| CLT | Cominco | CompanyDelisted |
| CLTH | Cleantech Biofuels | Company |
| CLTIX | Catalystlyons Tactical Allocation | Mutual Fund |
| CLTL | Invesco | ETF |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Calliditas Therapeutics AB reported net income of (500.29 Million). This is 246.59% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all United States stocks is 187.62% higher than that of the company.
Calliditas Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calliditas Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Calliditas Therapeutics could also be used in its relative valuation, which is a method of valuing Calliditas Therapeutics by comparing valuation metrics of similar companies.Calliditas Therapeutics is currently under evaluation in net income category among its peers.
Calliditas Fundamentals
| Return On Equity | -0.62 | |||
| Return On Asset | -0.25 | |||
| Profit Margin | (1.55) % | |||
| Current Valuation | 496.05 M | |||
| Shares Outstanding | 59.58 M | |||
| Shares Owned By Insiders | 14.22 % | |||
| Shares Owned By Institutions | 38.71 % | |||
| Price To Book | 5.22 X | |||
| Price To Sales | 14.67 X | |||
| Revenue | 229.35 M | |||
| Gross Profit | 229.35 M | |||
| EBITDA | (524.46 M) | |||
| Net Income | (500.29 M) | |||
| Total Debt | 189.16 M | |||
| Debt To Equity | 0.21 % | |||
| Current Ratio | 7.48 X | |||
| Cash Flow From Operations | (461.59 M) | |||
| Number Of Employees | 98 | |||
| Beta | 1.27 | |||
| Market Capitalization | 504.72 M | |||
| Total Asset | 1.46 B | |||
| Z Score | 1.2 | |||
| Net Asset | 1.46 B |
About Calliditas Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calliditas Therapeutics AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calliditas Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calliditas Therapeutics AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Calliditas Pink Sheet
Calliditas Therapeutics financial ratios help investors to determine whether Calliditas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Calliditas with respect to the benefits of owning Calliditas Therapeutics security.